Biosimulation Market Report 2026

Biosimulation Market Overview

• Biosimulation market size has reached to $4.98 billion in 2025 • Expected to grow to $11.11 billion in 2030 at a compound annual growth rate (CAGR) of 17.5% • Growth Driver: Global Healthcare Expenditure Boosts Biosimulation Market Growth • Market Trend: Enhancing Therapeutic Decision-making Through Advanced Biosimulation Tools • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biosimulation Market?

Biosimulation is a mathematical simulation process that uses computers to replicate biological processes and systems. The aim of biosimulation is a model-based prediction of the dynamics and behavior of biological systems. The main types of products in the biosimulation market are software and services. The biosimulation software provides software for molecular modelling and simulation, pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation, toxicity prediction software, physiologically based pharmacokinetic modeling, and simulation (PBPK) modelling and simulation, trial design software, and others. It is used in drug development, drug discovery, and others and implemented in various verticals such as pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, academic research institutions, others.

What Is The Biosimulation Market Growth Forecast?

The biosimulation market size is expected to see rapid growth in the next few years. It will grow to $11.11 billion in 2030 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to increasing demand for precision medicine modeling, rising investments in AI-driven biosimulation tools, expansion of in silico clinical trials, growing focus on reducing drug development timelines, increasing adoption of cloud-based biosimulation platforms. Major trends in the forecast period include increasing adoption of model-based drug development, rising use of pk and pd simulation platforms, growing integration of virtual clinical trials, expansion of disease modeling applications, enhanced focus on predictive toxicology modeling.

Global Biosimulation Market Segmentation

1) By Product: Software, Services 2) By Application: Drug Development, Drug Discovery, Other Applications 3) By End User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations (CROs), Academic Research Institutions, Other End Users Subsegments: 1) By Software: Pharmacokinetics (PK) Simulation Software, Pharmacodynamics (PD) Simulation Software, Toxicology Simulation Software, Disease Modeling Software, Integrated Biosimulation Platforms 2) By Services: Consulting Services, Model Development Services, Data Analysis And Interpretation Services, Training And Support Services, Custom Simulation Services

What Is The Driver Of The Biosimulation Market?

The surge in healthcare expenditure worldwide is expected to support the growth of the biosimulation market over the forecast period. Healthcare expenditure refers to the total amount of resources spent on healthcare goods and services, including drug development, clinical trials, and medical technology. The rise in healthcare spending is driven by growing demand for advanced medical treatments, aging populations, and increased investment in innovative drug development. The biosimulation market benefits directly from this trend as higher spending accelerates the adoption of computational modeling and simulation tools that enable virtual clinical trials and predictive disease modeling for drug development. For instance, in April 2025, according to the American Medical Association a US-based national professional association reported that health?care spending rose to US$?4.87?trillion in 2023, a 7.5% year?on?year increase, corresponding to about US$?14,570 per person. Therefore, the surge in healthcare expenditure worldwide is driving the growth of the biosimulation industry.

Key Players In The Global Biosimulation Market

Major companies operating in the biosimulation market are Certara Inc.; Dassault Systèmes SE; Schrödinger Inc.; Simulations Plus Inc.; Rhenovia Pharma SAS; Insilico Biotechnology AG; Genedata AG; Entelos Inc.; Physiomics plc; Rosa & Co. LLC.; In Silico Biosciences Inc.; INOSIM Software GmbH; LeadInvent Technologies Limited; Nuventra Pharma Sciences Inc.; Archimedes Inc.; VeriSIM Life Inc.; Compugen Inc.; Leadscope Inc.; Pharmaceutical Product Development LLC; Advanced Chemistry Development Inc.; Chemical Computing Group Inc.; Immunetrics and PPD Inc.; Instem India Private Limited; Evidera Inc.; Biomodels LLC; PhysioStim SA; Lhasa Limited; SimBioSys Inc.; Cadence Design Systems Inc.; Allucent Inc.

Global Biosimulation Market Trends and Insights

Major companies operating in the biosimulation market are focusing on developing advanced solutions, such as integrated pharmacokinetic-pharmacodynamic (PK-PD) modeling platforms, to enhance drug development efficiency, improve predictive accuracy, and accelerate therapeutic decision-making. Integrated PK-PD modeling platforms refer to software systems that simulate drug behavior and effects in virtual populations, enabling researchers to optimize dosing, predict outcomes, and reduce reliance on costly clinical trials. For instance, in August 2024, Certara, Inc, a US-based biosimulation and drug development company, launched Phoenix version 8.5, an advanced platform designed to streamline PK-PD modeling, population simulations, and clinical trial predictions. The software provides researchers with enhanced data analysis, visualization tools, and scenario testing to improve decision-making throughout drug development. By leveraging these biosimulation capabilities, the initiative supports faster, safer, and more cost-effective development of new therapies while optimizing clinical study design.

What Are Latest Mergers And Acquisitions In The Biosimulation Market?

In January 2023, Certara, Inc., a US based provider of biosimulation software, technology and services for drug discovery and development, acquired Vyasa Analytics, LLC for an undisclosed amount. With this acquisition, Certara aims to strengthen its software capabilities by integrating deep learning and data fabric technologies into its biosimulation offering. Vyasa Analytics is a US based provides biosimulation-related solutions through its advanced AI and deep-learning software platform.

Regional Insights

North America was the largest region in the biosimulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Biosimulation Market?

The biosimulation market includes revenues earned by entities by providing stimulation technology that provide simulations of biological processes and predict the behavior of biological systems to enhance the research and development (R&D) process. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biosimulation Market Report 2026?

The biosimulation market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biosimulation industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.